Phosphatidylinositol

Phosphatidylinositol

1. Identity, Chemical Names, and Common Forms

Phosphatidylinositol (abbreviated PI) is a glycerophospholipid and a member of the broader phospholipid family. It is a lipid which contains a phosphate group, two fatty acid chains, and one inositol sugar molecule. More precisely, phosphatidylinositol consists of a glycerol backbone esterified to two fatty acid chains and linked to an inositol ring through a phosphodiester bond. Typically, the phosphate group has a negative charge at physiological pH values; as a result, the molecule is amphiphilic.

Common synonyms and related designations include:

• 1,2-Diacyl-sn-glycero-3-phospho-(1D-myo-inositol) — the systematic IUPAC-based name
• Inositol phospholipid — used interchangeably in older literature
• Phosphoinositide (PI) — when referring collectively to PI and its phosphorylated derivatives

Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS) are the most abundant glycerophospholipids in nature. Phosphorylated forms of phosphatidylinositol are called phosphoinositides and play important roles in lipid signaling, cell signaling, and membrane trafficking.

The inositol ring can be phosphorylated by a variety of kinases on the three, four, and five hydroxyl groups in seven different combinations; however, the two and six hydroxyl groups are typically not phosphorylated due to steric hindrance. Multiple phosphorylation sites allow rapid conversion into signaling lipids such as PI3P, PI4P, PI(4,5)P2, and PI(3,4,5)P3.

In terms of fatty acid composition, the natural materials carry a range of unsaturated fatty acid derivatives at the sn-1 and sn-2 positions, and the nature and degree of saturation of the lipid chain is organism dependent. In soybean-derived PI, the main fatty acid found in phospholipid products is linoleic acid (C18:2n6), present in soybean at more than 65%.

The production of the phosphatidylinositol molecule is limited to the endoplasmic reticulum. The defining step in phosphatidylinositol biosynthesis is catalyzed by CDP-alcohol phosphotransferases, transmembrane enzymes that use CDP-diacylglycerol as donor substrate, and either inositol in eukaryotes or inositol phosphate in prokaryotes as the acceptor alcohol.

Common Commercial Forms and Preparations

Phosphatidylinositol is encountered commercially in several forms:

• Soy lecithin (crude or deoiled): Food-grade lecithins obtained from soya beans or other sources are a mixture containing about 60% phospholipids and 40% triglycerides, sterols, and carbohydrates in various proportions. The phospholipid composition of soya bean lecithin on an oil-free basis is 21% phosphatidylcholine, 22% phosphatidylethanolamine, and 19% phosphatidylinositol.
• Purified PI concentrate: Concentrated or isolated PI fractions can be produced by solvent fractionation. The alcohol-insoluble fraction is rich in the hydrophobic phosphatidylinositol and therefore favors the formation of water-in-oil emulsions.
• Capsules and softgels: Used in dietary supplement applications, often standardized to a defined percentage of PI within a total phospholipid mixture.

Natural phospholipids can be obtained from vegetable sources such as soybeans, sunflower, rape (canola) seed, wheat germ, and flax seed, and animal material such as hen egg yolk, milk, or krill. Globally, over 90% of commercial lecithin comes from soybeans; sunflower and egg are common alternatives.

2. Natural Sources

The chief source of commercial natural phospholipids are soybean, egg yolk, and cows (brain and liver). PI is a ubiquitous membrane constituent across all forms of life. Important phospholipids include phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol; their nature as amphiphilic molecules provides them with unique physicochemical properties, and their function as the principal components of cell membranes makes phospholipids essential for all vital cell processes.

In soybean lecithin, the main phospholipids are phosphatidylcholine (PC) at 55.3%, phosphatidylethanolamine (PE) at 26.3%, and phosphatidylinositol (PI) at 18.4%. In terms of total commercial soybean lecithin composition, commercial soybean lecithin is a complex mixture containing approximately 65–75% phospholipids together with triglycerides and smaller amounts of other substances; the major phospholipids include phosphatidylcholine, phosphatidylethanolamine, and inositol-containing phosphatides; other substances include carbohydrates, pigments, sterols, and sterol glycosides.

Beyond soybeans, soybean lecithin predominated by phosphatidylcholine, followed by phosphatidylethanolamine and phosphatidylinositol, provides an excellent source of phospholipids and fatty acids. PI is also found in meaningful quantities in egg yolk, animal brain and liver tissue, wheat germ, sunflower seeds, and marine sources including krill.

In the human body, the parent lipid phosphatidylinositol represents roughly 10% of total membrane phospholipids in the eukaryotic cell, while the phosphorylated derivatives account for only around 2–3%, with PI(4)P and PI(4,5)P2 representing the bulk of these lipids.

3. Historical and Traditional Use

Phosphatidylinositol and its derivatives have a rich history dating back to their discovery by Johann Joseph von Scherer and Léon Maquenne in the late 19th century. Initially known as "inosite" based on its sweet taste, the isolation and characterization of inositol laid the groundwork for understanding its cyclohexanol structure.

Inositol — the head-group component of PI — was first identified in muscle tissue in the mid-19th century by Scherer (1850). Its presence in soybean phosphatides was characterized scientifically in the 20th century. Inositol was first found in soybean phosphatides by Klenk and Sakai, with early work done by Woolley and Folch. This inositol compound corresponds to phosphatidylinositol (PI), for which the structure was determined by Okuhara and Nakayama.

Phosphatidylinositol does not have a defined traditional use in herbal or folk medicine as an isolated compound; it was not known or extractable as a pure entity in pre-modern pharmacopeias. However, inositol-rich foods — particularly organ meats, legumes, cereals, and nuts — have been consumed in all major food cultures throughout recorded history. The therapeutic use of inositol as a nutritional supplement emerged primarily in mid-20th-century nutritional biochemistry, when deficiency experiments in animals revealed its role in preventing conditions such as lipodystrophy (abnormal fat deposition). The broader category of phospholipid-rich lecithins (derived principally from soybeans and egg yolk) has been used in Western and Asian nutritional medicine from the early 20th century onward, first as a general tonic and later as a specific support for liver and cardiovascular health.

Recent advances in nutritional and biochemical research have documented inositol as an important dietary and cellular constituent. From early investigations into inositol's structure to the identification of its various isomers and their physiological functions, the study of inositol compounds continues to uncover new insights into cellular processes.

4. Key Constituents and Active Compounds

Phosphatidylinositol is itself the primary active entity rather than a carrier for distinct secondary metabolites. Its biological activity arises from its molecular architecture and the downstream signaling molecules it generates.

4.1 The Inositol Headgroup

The inositol (specifically myo-inositol) headgroup is the distinguishing structural feature of PI. Multiple phosphorylation sites allow rapid conversion into signaling lipids such as PI3P, PI4P, PI(4,5)P2, and PI(3,4,5)P3. High stereochemical specificity ensures precise binding to protein domains like PH, FYVE, and ENTH motifs.

4.2 The Phosphoinositide Family

The inositol headgroup can undergo reversible phosphorylation and dephosphorylation, leading to the formation of seven distinct phosphorylated species. Phosphoinositide composition of central nervous system cell membranes is fatty-acid enriched and consists primarily of phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PIP), and phosphatidylinositol-4,5-bisphosphate (PIP2).

4.3 Fatty Acid Side Chains

In animal tissues, phosphatidylinositol is the primary source of arachidonic acid for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2, which releases the fatty acids from position sn-2. 2-Arachidonoylglycerol, an endogenous ligand for the cannabinoid receptor, may be a further metabolite of phosphatidylinositol.

4.4 Diacylglycerol and Inositol Trisphosphate

Phospholipase C (PLC) plays a central role in the phosphoinositide signaling pathway by cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) into two important second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses through the cytoplasm and binds to receptors on the endoplasmic reticulum, triggering the release of calcium ions into the cytoplasm.

Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of sn-1,2-diacylglycerols that serve as signaling molecules in animal cells via the action of a family of enzymes collectively known as phospholipase C; diacylglycerols regulate a group of at least a dozen related enzymes known as protein kinase C, which in turn control many cellular processes, including differentiation, proliferation, metabolism, and apoptosis.

5. Mechanisms of Action

5.1 Structural Role in Cell Membranes

The function of phospholipids as the principal components of cell membranes makes them essential for all vital cell processes; they are widespread as secretory and structural components of the body and can mimic or enhance natural physiological processes. Functions of phosphatidylinositol in biological membranes include the regulation of cellular responses to external stimuli and/or nerve transmission, as well as the mediation of enzyme activity through interactions with various specific proteins.

5.2 The PI3K / Akt Signaling Cascade

The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates diverse cellular functions, including cell proliferation, survival, translational regulation of protein synthesis, glucose metabolism, cell migration, and angiogenesis. In receptor tyrosine kinase (RTK)-mediated signaling, PI3K is recruited to the plasma membrane upon RTK activation and phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3); this lipid product serves as a docking site for signaling proteins containing pleckstrin homology (PH) domains, including the protein kinase Akt, and Akt activation promotes cell survival, growth, and proliferation by phosphorylating various downstream targets.

PI3K signaling is modulated by multiple regulators, including growth factors (such as EGF, IGF-1, and FGF), hormones (such as estrogen and thyroid hormone), integrins, intracellular calcium levels, and RAS signaling. PI3K signaling is negatively regulated at the level of PIP3 clearance by phospholipid phosphatases, such as the phosphatase and tensin homologue (PTEN) protein and the inositol 5-phosphatase-2 (SHIP2) protein.

5.3 Calcium Signaling

Under the action of various physiological stimuli in animals, PI(4,5)P2 in the plasma membrane is hydrolyzed to release inositol 1,4,5-trisphosphate, a cellular messenger that diffuses into the cytosol and triggers calcium release from an ATP-loaded store. This calcium release from endoplasmic reticulum stores underlies numerous physiological processes including muscle contraction, secretion, and gene expression.

5.4 Endoplasmic Reticulum Function and Membrane Expansion

Reviews have attempted to explain why consuming extra myo-inositol, an essential component of membrane phospholipids, is often beneficial for patients with conditions characterized by insulin resistance, non-alcoholic fatty liver disease, and endoplasmic reticulum (ER) stress; it has been proposed that in the conditions that respond to dietary inositol there is an overstretching of inositol reserves that limits the stressed ER's ability to make the "extra" phosphatidylinositol needed for ER membrane expansion, and that consuming inositol supplements increases the inositol supply to inositol-deficient and ER-stressed cells, allowing them to make more PI and to expand the ER membrane system and sustain ER functions.

5.5 Cholesterol and Lipid Transport

Studies have shown that phosphatidylinositol can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of HDL-cholesterol to the liver and bile. These beneficial effects of phospholipids could be attributed to their ability to reduce intestinal cholesterol absorption, enhance biliary cholesterol excretion, and modulate the expression and activity of transcriptional factors and enzymes involved in lipoprotein metabolism.

5.6 GPI Anchor Formation

PI also serves as the precursor to glycosylphosphatidylinositol (GPI) anchors, which are used to attach certain proteins to the outer leaflet of the plasma membrane. In mammalian cells, the lipid precursor is a phosphatidylinositol molecule with 1-alkyl,2-acyl moieties, which is first attached via inositol to an N-acetylglucosamine residue, de-acetylated, and then translocated to the other side of the membrane by a flippase.

6. Body Systems and Health Areas

6.1 Cardiovascular System

In phase I/II clinical trials on patients with cardiovascular disease, phosphatidylinositol was given at doses over 5 g per day with only positive effects; it was shown to increase plasma high-density lipoprotein cholesterol and apolipoprotein A1 levels and reduce triglyceride levels without any evidence of toxicity.

A key human study, published in the Journal of Lipid Research, examined PI's effects directly in humans. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects; researchers performed a randomized 2-week study in 16 normolipidemic subjects who received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects, and PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. Minimal changes in plasma triglycerides were observed when PI was administered without food, whereas significant reductions were evident when taken with a meal; subjects who received PI with food all exhibited decreased triglycerides, ranging from 5% to 60%.

Evidence strength: This finding is based on a small randomized study (n=16) of short duration (2 weeks). While statistically significant effects on HDL-C and triglycerides were observed, the trial was limited in size and duration, and larger controlled trials have not been published as of the writing of this article.

6.2 Liver Health and Non-Alcoholic Fatty Liver Disease

Recent studies have shown that dietary phospholipids, especially phosphatidylcholine and phosphatidylserine, have various beneficial biological effects; however, there are not enough data concerning the physiological function of dietary phosphatidylinositol.

Animal (rodent) research has explored PI's hepatic effects directly. In the evaluation of the effect of dietary PI on cholesterol metabolism in metabolic syndrome model Zucker (fa/fa) rats, rats were fed semisynthetic diets containing either 7% soybean oil or 5% soybean oil plus 2% PI for 4 weeks; dietary PI prevented the mild hypercholesterolemia and hepatic cholesterol accumulation, and these effects were attributable to increased fecal bile acid excretion and tendencies of decreased ACAT1 mRNA level and increased CYP7A1 mRNA level in the liver.

Phosphatidylinositol and phosphatidylserine have been associated with reduced blood triglycerides, fatty liver disease, bipolar disorders, and neurodegenerative diseases; the deficiency of these phospholipids is also related to increased susceptibility to hepatic cancer.

Evidence strength: Evidence for PI's role in NAFLD and liver lipid metabolism is currently limited to animal models. Direct human clinical trials specifically on PI and liver disease have not yet been published in the peer-reviewed literature as of the research for this article.

6.3 Nervous System and Brain Function

The metabolism of PI gives rise to 7 known polyphosphoinositides (also known as phosphoinositides or phosphatidylinositol phosphates), which have prominent roles in signal transduction events in the central nervous system. Among lipid classes, glycerophospholipids are the foremost lipid class in the brain, serving as primary building blocks of the cell membrane; the composition of a cell's membrane is essential for various cellular functions including ion channels' regulation, neurotransmitter transport, and signal transduction.

Glycerophospholipids are also involved in myelin formation, which is responsible for insulating nerve fibers and allowing fast and efficient transmission of electrical impulses.

While phosphatidylserine (a closely related phospholipid) has been investigated in clinical trials for cognitive function, direct human trials specifically isolating the cognitive effects of phosphatidylinositol as a supplement are currently absent from the published peer-reviewed literature. The role of PI in neural signaling is established biochemically; however, its translation into clinical supplementation evidence for cognitive outcomes requires further research. Most studies have been performed in vitro or in animals, and only limited evidence is available for the benefit of phospholipid supplementation in humans; more research is needed to understand the impact of phospholipid supplementation and confirm its health benefits.

6.4 Insulin Sensitivity and Metabolic Health (Inositol / PCOS)

An important area of clinical research concerns inositol — the free headgroup compound that can be released from PI and that is a precursor to PI biosynthesis. Myo-inositol and D-chiro-inositol (stereoisomers of the inositol backbone) are increasingly studied in the context of insulin resistance and polycystic ovary syndrome (PCOS). Insulin resistance is common in women with polycystic ovary syndrome; inositol may have insulin sensitizing effects, but its efficacy in the management of PCOS remains indeterminate.

A 2024 systematic review and meta-analysis, published in the Journal of Clinical Endocrinology & Metabolism and intended to inform the 2023 international evidence-based PCOS guidelines, analyzed thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.

A 2024 umbrella review of meta-analyses from randomized controlled trials found that integrated analysis indicates that inositol significantly improves core hormonal, metabolic, and reproductive outcomes in PCOS patients, though all results in the analysis were rated as low-grade evidence quality and included only one study in some comparisons; outcomes should be interpreted with caution.

A prospective clinical study of myo-inositol in PCOS women reported a statistically significant decrease in luteinizing hormone (LH), LH/FSH ratio, fasting serum insulin levels, and HOMA-IR (homeostatic model assessment for insulin resistance). According to that study, myo-inositol led to a statistically significant improvement in the hormonal and metabolic profile of PCOS patients, and was reported to be safe with good compliance.

The inositol complex acts as a second messenger of insulin signaling; both myo-inositol and D-chiro-inositol have insulin-like action and have been claimed to improve various menstrual and hormonal parameters in PCOS.

Evidence strength: It is important to note that most of this inositol/PCOS clinical research pertains to free inositol (myo-inositol or D-chiro-inositol), not to phosphatidylinositol as a dietary supplement per se. PI is a reservoir of inositol in cell membranes and foods, and free inositol can be derived from PI via phospholipase action. The mechanistic relationship is established, but it is not established whether supplementing with PI as a phospholipid produces the same hormonal and metabolic outcomes as supplementing with free inositol.

6.5 Endoplasmic Reticulum Stress and Systemic Disease

This area proposes that consuming extra myo-inositol, an essential component of membrane phospholipids, is often beneficial for patients with conditions characterized by insulin resistance, non-alcoholic fatty liver disease, and endoplasmic reticulum stress. The review further reinterprets historical data on inositol deficiency as involving failure of cells to adapt adequately to ER stress, proposing that dietary inositol allows cells to make more phosphatidylinositol, thereby enabling ER membrane expansion and sustained ER function. This mechanism, while compelling, is theoretical-to-preliminary and has not yet been directly verified in large-scale human trials.

6.6 Cell Growth, Proliferation, and Cancer-Related Signaling

The class I phosphoinositide 3-kinase signaling pathway is a dynamic regulator of physiological and cellular processes including cell proliferation, growth, survival, migration, and metabolism. The PI3K pathway is commonly dysregulated in human cancer, and drives tumorigenesis by promoting aberrant cell growth and transformation; hyperactivation of PI3K/AKT signaling frequently occurs in human cancers, making it an attractive therapeutic target. These findings, while highly relevant to oncology drug development, pertain to pharmaceutical inhibition of PI-derived pathways — not to dietary PI supplementation.

7. Scientific Evidence by Area: Summary Table

• Lipid/cholesterol metabolism (human): One small randomized trial (n=16, 2 weeks) found significant HDL-C elevation and triglyceride reduction with PI 2.8–5.6 g/day taken with food. Phase I/II cardiovascular trials also reported benefits at >5 g/day. Evidence is preliminary due to small sample sizes.
• Fatty liver / hepatic lipid metabolism: Evidence currently limited to animal studies (Zucker rat models). No published human clinical trials specifically on PI supplementation and NAFLD.
• Cognitive and neurological function: PI is a critical structural and signaling component of neural membranes, but no published human clinical trials have specifically tested PI supplementation for cognitive outcomes as of this writing.
• Insulin resistance / PCOS: Extensive clinical trial evidence exists for free inositol (myo-inositol, D-chiro-inositol) — but not specifically for phosphatidylinositol as a dietary phospholipid supplement.
• ER stress and membrane function: Mechanistic review-level evidence only; no clinical trials.
• Cancer pathways: PI-derived pathways are well-characterized targets in oncology pharmacology, but this does not constitute evidence for dietary PI supplementation in cancer prevention or treatment.

8. Dosage Forms and Doses Reported in Studies

The following doses have been reported in the peer-reviewed literature. These are descriptive, not prescriptive.

• Human cardiovascular trial (Journal of Lipid Research, 2004): A randomized 2-week study in 16 normolipidemic subjects, who received either 2.8 or 5.6 g of PI, with or without food.
• Phase I/II cardiovascular clinical trials: Phosphatidylinositol was given at doses over 5 g per day with only positive effects.
• Animal (rat) study — cholesterol metabolism: Rats were fed semisynthetic diets containing either 7% soybean oil or 5% soybean oil plus 2% PI for 4 weeks.
• Toxicity study (rat, oral): Up to 2,000 mg/kg of purified PI was administered once orally to male and female rats with no deaths or any clinical signs; subsequently, PI was repeatedly administered at daily doses of 100, 300, and 1,000 mg/kg for 13 weeks.

No universally accepted standardized dosage range for phosphatidylinositol as a dietary supplement has been established by regulatory bodies such as the NIH Office of Dietary Supplements or EFSA.

9. Safety Considerations and Known Interactions

9.1 General Toxicology

Although phosphatidylinositol is an important component in all plants and animals, there is no toxicity report when purified PI is orally administered to animals. A formal safety study of purified soy-derived PI (Asahi Kasei PI) conducted acute, subchronic, and genotoxicity evaluations. Neither death nor any toxicological signs during the administration period nor changes related to the test substance were observed with regard to body weight, food consumption, ophthalmoscopy, hematology, blood biochemistry, necropsy, organ weights, or histopathology. The no-observed-adverse-effect level (NOAEL) of Asahi Kasei PI was considered to be 1,000 mg/kg/day for male and female rats.

Genotoxicity evaluation was carried out by the bacterial reverse mutation test (Ames test) and in vitro chromosome aberration test; the results indicate neither increases of revertant colonies nor chromosome aberration, suggesting that the purified soy PI has high safety in genotoxicity.

9.2 EFSA Evaluation of Lecithins (E 322)

The European Food Safety Authority has conducted a formal re-evaluation of lecithins as a food additive (E 322), which contains PI as a significant component. Subchronic toxicity studies in rats and dogs did not report any adverse effect, even at the highest doses tested (3,750 mg essential phospholipid/kg body weight per day, 1,000 mg soya phosphatidylinositol or EPL/kg bw per day in rats and dogs, respectively, and 5,460 mg lecithins/kg bw per day in rats). The Panel considered the available genotoxicity data on lecithins to be sufficient to conclude that there is no concern with respect to genotoxicity. Chronic toxicity studies in rats did not report any adverse effects even at the highest dose tested (3,750 mg EPL/kg bw per day); no carcinogenic effects were reported in rats even at the highest dose tested (1,470 and 2,280 mg soya lecithin/kg bw per day in males and females, respectively) for 2 years.

9.3 Soy Allergy

According to the EFSA NDA Panel, the lowest minimum eliciting dose (MED) reported in soy-allergic patients undergoing double-blind placebo-controlled food challenge was 0.2 mg of soya protein, although the majority of patients only reacted to higher doses. The Panel also noted some case reports of hypersensitivity reactions associated with egg and soya lecithins. Individuals with documented soy allergy should exercise caution with soy-derived PI preparations and consider sunflower- or egg-derived alternatives.

9.4 Food Additive Regulatory Status

Regulatory agencies (FDA, EFSA) regard lecithin as safe (GRAS / E322) at typical use levels. Phosphatidylinositol, as a component of lecithin, therefore falls under this general safety designation in food contexts. However, as an isolated supplement at pharmacological doses, it has not received specific drug approval or an official dietary reference intake (DRI) designation in the US or EU.

9.5 Interactions and Special Populations

Given their extreme safety and biocompatibility, dietary supplementation with phospholipid preparations, in particular phosphatidylinositol, appears as a novel and effective strategy that could be used as an alternative or adjunctive therapy to current medications. No specific drug-drug interactions for isolated PI supplementation have been identified in the peer-reviewed literature reviewed for this article. As PI is a substrate for PI3K — a pathway central to insulin signaling — theoretically, high-dose PI supplementation might interact with PI3K inhibitor drugs used in oncology, though this has not been evaluated clinically.

PI supplementation studies do not specifically address safety in pregnancy, lactation, pediatric populations, or in individuals with severe hepatic or renal impairment; these populations have not been formally studied in published clinical trials on PI.

References

• LIPID MAPS LipidWeb: Phosphatidylinositol, phosphatidylinositol phosphates and related phosphoinositides — structure, composition, biochemistry, and analysis
• Younes M, et al. Re-evaluation of lecithins (E 322) as a food additive. EFSA Journal. PMC7010002
• Imaizumi K, et al. Effect of dietary phosphatidylinositol on cholesterol metabolism in Zucker (fa/fa) rats. PubMed 19202308
• Holub BJ. Do inositol supplements enhance phosphatidylinositol supply and thus support endoplasmic reticulum function? PubMed 29859544
• Burgess JW, et al. Phosphatidylinositol increases HDL-C levels in humans. Journal of Lipid Research, 2004
• Küllenberg D, et al. Health effects of dietary phospholipids. Lipids in Health and Disease. PMC3316137
• Kudo N, et al. Toxicity studies of Asahi Kasei PI, purified phosphatidylinositol from soy lecithin. PubMed 19483381
• Fitz V, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. PMC11099481
• The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. PMC10926319
• Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. PMC12932251
• Chénard T, et al. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. PMC5301276
• Fruman DA, et al. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells. PMC3414724
• Clarke OB, et al. Structural basis for phosphatidylinositol-phosphate biosynthesis. Nature Communications. PMC4634129
• Sarmento MJ, et al. Structure and Lateral Organization of Phosphatidylinositol 4,5-bisphosphate. PMC7503891
• Gurnida DA, et al. Dietary Polar Lipids and Cognitive Development: A Narrative Review. PMC6855982
• Sahebkar A, et al. Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia. Biochimica et Biophysica Acta. ScienceDirect
• Scholfield CR. Composition of soybean lecithin. Journal of the American Oil Chemists' Society. 1981
• Phospholipidomics in Clinical Trials for Brain Disorders: Advancing our Understanding and Therapeutic Potentials. PMC11087356
• Phosphatidylinositol — Wikipedia